AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2513206
Drug: Verapamil 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 320 mg/day
Trial: 5303665
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: one dose of 1 ml of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Trial: 5303665
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 2 doses (1 ml each) of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Trial: 5303665
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: one dose of cholera El Tor vaccine containing 16 x 10(9) organisms/ml
Trial: 5303665
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 2 doses of typhoid vaccine
Trial: 31221888
Drug: rhinothermy delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhinothermy delivered by nasal high flow therapy (rNHF) at 41°C for 2 hours daily for five days
Trial: 23741829
Drug: Lincomycin hydrochloride
RxNorm normalized name: Lincomycin Hydrochloride
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lincomycin hydrochloride 500 mg capsules
Trial: 23741829
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 200 mg tablets
Trial: 7003855
Drug: Diethylcarbamazine (DEC)
RxNorm normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylcarbamazine (DEC) lotion, applied daily for seven days, then weekly for seven weeks
Trial: 31544378
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and moxibustion therapy of Tiaochongren Gushenyuan
Trial: 29037576
Drug: Maternal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal vaccination during pregnancy (not specified dosage or duration)
Trial: 18285589
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass azithromycin administration
Trial: 16355608
Drug: Changji' an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changji' an (CJA) oral liquid
Trial: 12804182
Drug: ATG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG treatment for GVHD prophylaxis
Trial: 12804182
Drug: No ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ATG treatment for GVHD prophylaxis
Trial: 10588209
Drug: 50-mg bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg bolus of recombinant tissue-type plasminogen activator (rt-PA)
Trial: 8475268
Drug: Uniphasic injection
RxNorm normalized name: insulin isophane, pork / insulin, regular, pork Injectable Suspension [Hypurin Porcine Biphasic Isophane]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphasic injection protocol
Trial: 3515925
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of intramuscular morphine sulfate
Trial: 31564356
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection on a monthly basis for 3 months, followed by bimonthly injections for another 9 months.
Trial: 25595177
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection
Trial: 24777811
Drug: Control (Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Atorvastatin 10 mg during run-in period)
Trial: 24659566
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg/day for 12 weeks
Trial: 24659566
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg/day for 24 weeks
Trial: 17908130
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention with treatment fidelity procedures (specific details on dosage and duration not available)
Trial: 17908130
Drug: Treatment fidelity
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment fidelity procedures applied in the SPHERE study
Trial: 17908130
Drug: Behavior Change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior Change Consortium's model of treatment fidelity
Trial: 14684407
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral doses of 100 mg elemental Fe and 500 micro g folic acid
Trial: 14684407
Drug: 3 intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 intramuscular doses of 250 mg elemental Fe as iron dextran at 1‐mo intervals and oral doses of 5 mg folic acid twice weekly
Trial: 6121479
Drug: Intravenous atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atenolol (5 to 15 mg)
Trial: 19238808
Drug: Caffeine, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine, 600 mg (n=12)
Trial: 19238808
Drug: Modafinil, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil, 400 mg (n=12)
Trial: 11607890
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol + vaginal progesterone (Group 2)
Trial: 11607890
Drug: Oral oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestradiol + vaginal progesterone (Group 3)
Trial: 11607890
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without therapy (Group 4)
Trial: 8032838
Drug: Clean intermittent
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean intermittent catheterization (CIC) weekly for 1 year
Trial: 1922166
Drug: L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1 g/orally b.i.d.)
Trial: 6763836
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment programme
Trial: 6763836
Drug: Cardiological measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiological measures (e.g. diet, exercise, adherence to medication)
Trial: 31302644
Drug: Sham opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham opioid infusion (saline solution)
Trial: 25720388
Drug: Subcutaneous exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous exenatide for 11 days
Trial: 19809230
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection of 9 ml bupivacaine and 1 ml betamethasone
Trial: 17520986
Drug: Intranasal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal sufentanil (2 microg/kg)
Trial: 17520986
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg/kg in cherry juice)
Trial: 17520986
Drug: Oral tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol (3 mg/kg drops)
Trial: 15567986
Drug: Recombinant HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant HBV vaccine (20 microg doses at months 0, 1, and 6)
Trial: 12368393
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g FOS + 80 mg cornstarch
Trial: 12368393
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g sucrose + 80 mg cornstarch
Trial: 7985753
Drug: Malaria sporozoite
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria sporozoite vaccine (R32NS1(81))
Trial: 30926654
Drug: Gastric cancer
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric cancer risk prediction rule (based on age, sex, PG I/II ratio, G-17 level, H. pylori infection, pickled food, fried food)
Trial: 25188398
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) control condition over 4 months
Trial: 11234653
Drug: Multivitamin-mineral combination
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin-mineral combination (Berocca Calmag)
Trial: 31870634
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg daily for 26 weeks
Trial: 26738641
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement therapy (MET) and strengths-based case management (SBCM)
Trial: 31634025
Drug: IIV4-HD by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-HD by subcutaneous injection
Trial: 31634025
Drug: IIV4-SD by
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-SD by subcutaneous injection
Trial: 31634025
Drug: IIV4-HD by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4-HD by intramuscular injection
Trial: 27664002
Drug: Stop/reduce vasoactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop/reduce vasoactive therapy
Trial: 27664002
Drug: Continue vasoactive
RxNorm normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue vasoactive therapy
Trial: 19682111
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (higher-dose)
Trial: 9829367
Drug: AO-128 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO-128 (2 mg three times daily)
Trial: 12563
Drug: Intravenous 10
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10 mg tolamolol
Trial: 12563
Drug: Intravenous 5
RxNorm normalized name: immune globulin intravenous 5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5 mg bufuralol
Trial: 16722155
Drug: Conservative medical
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative medical therapy (Group A)
Trial: 9282303
Drug: Scopolamine butylbromide
RxNorm normalized name: Scopolamine butylbromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine butylbromide at a daily dose of 60 mg t.i.d. (Group B)
Trial: 3028457
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg enalapril orally
Trial: 29914530
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (6 g)
Trial: 12534645
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg twice daily for 7 days
Trial: 27128837
Drug: GSK961081 800 µg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GSK961081 800 µg and FP 500 µg concurrently via separate inhalers
Trial: 27128837
Drug: FP 500 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 500 µg alone
Trial: 19198268
Drug: Ozonotherapy (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozonotherapy (intravenous infusion of ozonized physiological solution)
Trial: 1894523
Drug: Lung hyperinflation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung hyperinflation and suctioning (three lung hyperinflation breaths at volumes of 12 cc/kg, 14 cc/kg, 16 cc/kg, or 18 cc/kg of lean body weight, followed by 10 seconds of continuous suction)
Trial: 6873137
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.3 mg and 0.9 mg (oral)
Trial: 6873137
Drug: Scopolamine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.9 mg b.d. for 3 days (oral)
Trial: 6873137
Drug: Ephedrine (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (alone and in combination with scopolamine)
Trial: 6873137
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.9 mg (oral)
Trial: 6621852
Drug: Scopolamine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (various doses)
Trial: 25128002
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training plus solifenacin (5 mg once daily)
Trial: 17210771
Drug: Posaconazole at
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole at 800 mg/day as an oral suspension in divided doses
Trial: 10863225
Drug: Augmented betamethasone
RxNorm normalized name: Augmented betamethasone dipropionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented betamethasone dipropionate 0.05% cream once daily in the first and third weeks and calcipotriene 0.005% ointment twice daily in the second and fourth weeks
Trial: 10863225
Drug: Daily augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily augmented betamethasone dipropionate 0.05% cream for 4 weeks
Trial: 26993881
Drug: Diclofenac (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (75 mg/3 mL intramuscular)
Trial: 26993881
Drug: Paracetamol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1 g/100 mL intravenous)
Trial: 26993881
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg intravenous)
Trial: 22313885
Drug: Qingre Huayu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Huayu herbs plus classic Western medical treatment (treatment group)
Trial: 22313885
Drug: Classic Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classic Western medical treatment (control group)
Trial: 10488294
Drug: Flumazenil administered
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil administered at the conclusion of the surgical procedure
Trial: 10488294
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the conclusion of the surgical procedure
Trial: 21564406
Drug: 17α-hydroxyprogesterone caproate
RxNorm normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17α-hydroxyprogesterone caproate 250 mg intramuscularly weekly from 16 weeks' gestation to 37 weeks' gestation
Trial: 2308758
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of morphine (PCA)
Trial: 3919746
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of morphine
Trial: 26585409
Drug: Antipsychotic review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic review
Trial: 27640872
Drug: Antipsychotic review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic review and social interaction
Trial: 25520427
Drug: Antimalarial chemoprevention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimalarial chemoprevention
Trial: 19168412
Drug: Test ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test ciprofloxacin (500 mg)
Trial: 8431747
Drug: Anaesthetic solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic solution at 18 degrees C
Trial: 8431747
Drug: Anaesthetic solution
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaesthetic solution at 37 degrees C
Trial: 3038415
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg once-a-day
Trial: 22541755
Drug: Moprid® (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moprid® (5 mg mosapride citrate tablets)
Trial: 22541755
Drug: Gasmotin® (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gasmotin® (5 mg mosapride citrate tablets)
Trial: 17589809
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (IVT) 4 mg
Trial: 2177158
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ACTH 4-10
Trial: 21990397
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + bevacizumab
Trial: 20516273
Drug: Meal E
RxNorm normalized name: Oat meal extract
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal E (200 ml of water)
Trial: 18822919
Drug: Retention enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retention enema with compound glutamine entero‐soluble Capsule (CGC) and oral CGC (0.8 g, thrice a day)
Trial: 15907596
Drug: FURP-lamivudine (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FURP-lamivudine (test formulation)
Trial: 15907596
Drug: Epivir (reference
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epivir (reference formulation)
Trial: 8867907
Drug: GHRH (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH (100 micrograms in 1 ml saline)
Trial: 8867907
Drug: Galanin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galanin (10 micrograms/kg in 100 ml saline) infusion for 60 minutes
Trial: 8867907
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of galanin (10 micrograms/kg in 100 ml saline) and GHRH (100 micrograms in 1 ml saline)
Trial: 1611439
Drug: MF 701
RxNorm normalized name: 3-MF
DrugBank: 3-Methylfentanyl (DB01571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF 701 (100 mg intramuscularly once a day)
Trial: 1611439
Drug: UFH (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH (5000 units subcutaneously three times daily)
Trial: 6422900
Drug: 5-hydroxytryptophan (5-HTP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (5-HTP), 200 mg orally
Trial: 31299912
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention including an oral 20-25 min presentation in the language of participants about cervical cancer and screening.
Trial: 20572865
Drug: Buccal brackets
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal brackets
Trial: 20359269
Drug: Evening Primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening Primrose Oil (EPO) 3,000 mg per day
Trial: 18786318
Drug: Heparin 2
RxNorm normalized name: heparin 2 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 2 mg.kg(‐1).d(‐1) administered continuously via intravenous pump
Trial: 14703408
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy + radiotherapy (GTRT group, n = 20) - SBN‐1 solution 1 x 10(12) VP injected intratumorally once a week for 8 weeks, radiotherapy started on the 3rd day of gene therapy, 5 fractions a week with a fraction dosage of 2 Gy and total dosage of 70 Gy
Trial: 27565435
Drug: IIV4 (quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIV4 (quadrivalent influenza vaccine)
Trial: 11902593
Drug: Weekly plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly plasma exchange, oral cyclophosphamide, and prednisone
Trial: 11902593
Drug: Sham plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham plasma exchange and placebo medications
Trial: 9295106
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (2 mg)
Trial: 30247596
Drug: Recombinant adjuvanted
RxNorm normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adjuvanted zoster vaccine (HZ/su), administered in 2 doses separated by 60 days
Trial: 30247596
Drug: Recombinant adjuvanted
RxNorm normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant adjuvanted zoster vaccine (HZ/su)
Trial: 29328644
Drug: Triple eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple eradication therapy with probiotics (Lactobacillus Rosell‐52, Lactobacillus Rosell‐11, Bifidobacterium Rosell‐1755, Saccharomyces boulardii)
Trial: 29328644
Drug: Triple eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple eradication therapy without probiotics
Trial: 29328644
Drug: Triple eradication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple eradication therapy with probiotics